New hope for kidney transplant patients battling BK virus
NCT ID NCT04542733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two drug combinations to treat BK virus infection in kidney transplant recipients. BK virus can cause the new kidney to fail. The trial compares everolimus with a lower dose of tacrolimus versus a lower dose of tacrolimus plus leflunomide in 50 adults whose virus did not clear after reducing their usual anti-rejection medicines. The main goal is to see which combination lowers the virus level more over six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BK VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, 10330, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Can 'Supercharged' donor cells beat viruses that drugs Can't?
- Transplant breakdown? new study checks organ fluid for hidden germs
- Banked immune cells show promise against Life-Threatening viruses in transplant patients
- Donor immune cells take on tough viruses in transplant patients